The Use of HSQoL-24 in an Assessment of Quality-of-Life Impairment among Hidradenitis Suppurativa Patients: First Look at Real-Life Data
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Group
2.2. Quality of Life
2.3. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Chernyshov, P.V. The Evolution of Quality of Life Assessment and Use in Dermatology. Dermatology 2019, 235, 167–174. [Google Scholar] [CrossRef] [PubMed]
- Singh, S.; Ehsani-Chimeh, N.; Kornmehl, H.; Armstrong, A.W. Quality of life among dermatology patients: A systematic review of investigations using qualitative methods. G. Ital. Dermatol. E Venereol. 2019, 154, 72–78. [Google Scholar] [CrossRef]
- Finlay, A.; Khan, G. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin. Exp. Dermatol. 1994, 19, 210–216. [Google Scholar] [CrossRef] [PubMed]
- Finlay, A.Y.; Salek, M.S.; Abeni, D.; Tomás-Aragonés, L.; Van Cranenburgh, O.D.; Evers, A.W.; Jemec, G.B.; Linder, D.; Manolache, L.; Marrón, S.E.; et al. Why quality of life measurement is important in dermatology clinical practice: An expert-based opinion statement by the EADV Task Force on Quality of Life. J. Eur. Acad. Dermatol. Venereol. 2017, 31, 424–431. [Google Scholar] [CrossRef] [Green Version]
- Del Duca, E.; Morelli, P.; Bennardo, L.; Di Raimondo, C.; Nisticò, S.P. Cytokine Pathways and Investigational Target Therapies in Hidradenitis Suppurativa. Int. J. Mol. Sci. 2020, 21, 8436. [Google Scholar] [CrossRef]
- Krajewski, P.; Matusiak, Ł.; von Stebut, E.; Schultheis, M.; Kirschner, U.; Nikolakis, G.; Szepietowski, J. Quality-of-Life Impairment among Patients with Hidradenitis Suppurativa: A Cross-Sectional Study of 1795 Patients. Life 2021, 11, 34. [Google Scholar] [CrossRef]
- Chernyshov, P.; Finlay, A.; Tomas-Aragones, L.; Poot, F.; Sampogna, F.; Marron, S.; Zemskov, S.; Abeni, D.; Tzellos, T.; Szepietowski, J.; et al. Quality of Life in Hidradenitis Suppurativa: An Update. Int. J. Environ. Res. Public Health 2021, 18, 6131. [Google Scholar] [CrossRef]
- Marrón, S.; Gómez-Barrera, M.; Tomás-Aragonés, L.; Díaz, R.D.; Rull, E.V.; Álvarez, M.M.; Puig, L. Development and Preliminary Validation of the HSQoL-24 Tool to Assess Quality of Life in Patients With Hidradenitis Suppurativa. Actas Dermo-Sifiliogr. 2019, 110, 554–560. [Google Scholar] [CrossRef]
- Marron, S.; Gomez-Barrera, M.; Aragones, L.; Goni-Navarro, A.; Vilarrasa, E.; Diaz-Diaz, R.; Aranibar, F.; Campos-Rodenas, R.; Barrio, V.; Gilaberte-Calzada, Y.; et al. Quality of Life in Hidradenitis Suppurativa: Validation of the HSQoL. Acta Derm. Venereol. 2021, 101, adv00529. [Google Scholar] [CrossRef]
- Zouboulis, C.P.D.; Del Marmol, V.; Mrowietz, U.U.; Prens, E.; Tzellos, T.T.; Jemec, G. Hidradenitis Suppurativa/Acne Inversa: Criteria for Diagnosis, Severity Assessment, Classification and Disease Evaluation. Dermatology 2015, 231, 184–190. [Google Scholar] [CrossRef] [PubMed]
- Sabat, R.; Jemec, G.B.; Matusiak, Ł.; Kimball, A.B.; Prens, E.; Wolk, K. Hidradenitis suppurativa. Nat. Rev. Dis. Primers 2020, 6, 18. [Google Scholar] [CrossRef] [PubMed]
- Kurokawa, I.; Hayashi, N. Questionnaire surveillance of hidradenitis suppurativa in Japan. J. Dermatol. 2015, 42, 747–749. [Google Scholar] [CrossRef]
- Jemec, G. The symptomatology of hidradenitis suppurativa in women. Br. J. Dermatol. 1988, 119, 345–350. [Google Scholar] [CrossRef]
- Goldburg, S.R.; Strober, B.E.; Payette, M.J. Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis. J. Am. Acad. Dermatol. 2020, 82, 1045–1058. [Google Scholar] [CrossRef]
- Zouboulis, C.C.; Desai, N.; Emtestam, L.; Hunger, R.E.; Ioannides, D.; Juhász, I.; Lapins, J.; Matusiak, L.; Prens, E.P.; Revuz, J.; et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne in-versa. J. Eur. Acad. Derm. Venereol. 2015, 29, 619–644. [Google Scholar] [CrossRef]
- Matusiak, Ł.; Bieniek, A.; Szepietowski, J. Psychophysical Aspects of Hidradenitis Suppurativa. Acta Derm. Venereol. 2010, 90, 264–268. [Google Scholar] [CrossRef] [Green Version]
- Włodarek, K.; Głowaczewska, A.; Matusiak, Ł.; Szepietowski, J.C. Psychosocial burden of Hidradenitis Suppurativa patients’ partners. J. Eur. Acad. Dermatol. Venereol. 2020, 34, 1822–1827. [Google Scholar] [CrossRef]
- Matusiak, Ł.; Bieniek, A.; Szepietowski, J.C. Hidradenitis suppurativa markedly decreases quality of life and professional ac-tivity. J. Am. Acad. Dermatol. 2010, 62, 706–708. [Google Scholar] [CrossRef]
- Theut Riis, P.; Thorlacius, L.; Knudsen List, E.; Jemec, G.B.E. A pilot study of unemployment in patients with hidradenitis sup-purativa in Denmark. Br. J. Dermatol. 2017, 176, 1083–1085. [Google Scholar] [CrossRef] [PubMed]
- Glowaczewska, A.; Reszke, R.; Szepietowski, J.C.; Matusiak, L. Indirect Self-Destructiveness in Hidradenitis Suppurativa Pa-tients. J. Clin. Med. 2021, 10, 4194. [Google Scholar] [CrossRef] [PubMed]
- Matusiak, Ł. Profound consequences of hidradenitis suppurativa: A review. Br. J. Dermatol. 2020, 183, e171–e177. [Google Scholar] [CrossRef]
- Chren, M.M.; Lasek, R.J.; Flocke, S.A.; Zyzanski, S.J. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch. Dermatol. 1997, 133, 1433–1440. [Google Scholar] [CrossRef] [PubMed]
- EuroQol-Group. EuroQol—A new facility for the measurement of health-related quality of life. Health Policy 1990, 16, 199–208. [Google Scholar] [CrossRef]
- Ware, J.E., Jr.; Sherbourne, C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 1992, 30, 473–483. [Google Scholar] [CrossRef] [PubMed]
- Frings, V.G.; Bauer, B.; Glöditzsch, M.; Goebeler, M.; Presser, D. Assessing the psychological burden of patients with hidradeni-tis suppurativa. Eur. J. Dermatol. 2019, 29, 294–301. [Google Scholar] [PubMed]
- Jørgensen, A.R.; Holm, J.G.; Ghazanfar, M.N.; Yao, Y.; Ring, H.C.; Thomsen, S.F. Factors affecting quality of life in patients with hid-radenitis suppurativa. Arch. Dermatol. Res. 2020, 312, 427–436. [Google Scholar] [CrossRef]
- Kouris, A.; Platsidaki, E.; Christodoulou, C.; Efstathiou, V.; Dessinioti, C.; Tzanetakou, V.; Korkoliakou, P.; Zisimou, C.; Antoniou, C.; Kontochristopoulos, G. Quality of Life and Psychosocial Implications in Patients with Hidradenitis Suppurativa. Dermatology 2016, 232, 687–691. [Google Scholar] [CrossRef]
- Thorlacius, L.; Esmann, S.; Miller, I.; Vinding, G.; Jemec, G.B. Development of HiSQOL: A Hidradenitis Suppurativa-Specific Quality of Life Instrument. Ski. Appendage Disord. 2019, 5, 221–229. [Google Scholar] [CrossRef] [PubMed]
- Krajewski, P.; Matusiak, Ł.; Szepietowska, M.; Rymaszewska, J.; Jemec, G.; Kirby, J.; Szepietowski, J. Hidradenitis Suppurativa Quality of Life (HiSQOL): Creation and validation of the Polish language version. Adv. Dermatol. Allergol. Postępy Dermatol. I Alergol. 2020, 37. [Google Scholar] [CrossRef]
- Kirby, J.; Thorlacius, L.; Villumsen, B.; Ingram, J.; Garg, A.; Christensen, K.; Butt, M.; Esmann, S.; Tan, J.; Jemec, G. The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: Development and validation of a measure for clinical trials. Br. J. Dermatol. 2019, 183, 340–348. [Google Scholar] [CrossRef]
- Bidaki, R.; Majidi, N.; Ahmadi, A.M.; Bakhshi, H.; Mohammadi, R.S.; Mostafavi, S.-A.; Arababadi, M.K.; Hadavi, M.; Mirzaei, A. Vitiligo and social acceptance. Clin. Cosmet. Investig. Dermatol. 2018, 11, 383–386. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Łakuta, P.; Marcinkiewicz, K.; Bergler-Czop, B.; Brzezińska-Wcisło, L. How does stigma affect people with psoriasis? Adv. Dermatol. Allergol. 2017, 1, 36–41. [Google Scholar] [CrossRef] [PubMed]
- Nicholas, M.N.; Gooderham, M.J. Atopic Dermatitis, Depression, and Suicidality. J. Cutan. Med. Surg. 2017, 21, 237–242. [Google Scholar] [CrossRef] [PubMed]
Characteristics | Result |
---|---|
Sex, number of participants (%): | |
| 108 (31.6) |
| 234 (68.4) |
Age, number of participants (%): | |
| 90 (26.3) |
| 247 (72.2) |
| 5 (1.5) |
| 37.5 ± 10.7 |
Weight: | |
| 82.0 ± 17.3 |
Height: | |
| 167.4 ± 8.8 |
Body mass index (BMI): | |
| 29.3 ± 6.1 |
Living situation, number of participants (%): | |
| 59 (17.3) |
| 189 (55.3) |
| 94 (27.5) |
Education level, number of participants (%): | |
| 50 (14.6) |
| 142 (41.5) |
| 150 (43.9) |
Employment, number of participants (%): | |
| 48 (14.0) |
| 178 (52.0) |
| 20 (5.8) |
| 69 (20.2) |
| 27 (7.9) |
Current HS severity, number of participants (%): | |
| 129 (37.7) |
| 101 (29.5) |
| 112 (32.7) |
Hurley stage, number of participants (%): | |
| 64 (18.7) |
| 147 (43.0) |
| 131 (38.3) |
Duration of the disease, number of participants (%): | |
| 73 (21.3) |
| 53 (15.5) |
| 216 (63.2) |
| 15.9 ± 10.7 |
Number of localizations: | |
| 2.5 ± 1.3 |
HSQoL-24 result: | |
| 58.3 ± 21.0 |
HSQoL-24 domains, mean ± SD (points): | |
| 58.9 ± 21.6 |
| 50.8 ± 36.2 |
| 63.0 ± 31.3 |
| 66.0 ± 27.8 |
| 37.4 ± 25.1 |
| 62.9 ± 25.7 |
Domain, Mean ± SD (Points) | Men, n = 108 | Women, n = 234 | p |
---|---|---|---|
HRSQoL-24 Global | 51.1 ± 23.1 | 61.6 ± 19.2 | <0.001 |
HRSQoL-24 Psychosocial | 51.3 ± 23.6 | 62.3 ± 19.7 | <0.001 |
HRSQoL-24 Economic | 39.3 ± 35.5 | 56.0 ± 35.3 | <0.001 |
HRSQoL-24 Occupational | 58.9 ± 33.3 | 64.9 ± 30.2 | 0.102 |
HRSQoL-24 Relationships | 57.0 ± 27.7 | 70.2 ± 26.8 | <0.001 |
HRSQoL-24 Personal | 35.0 ± 27.3 | 38.5 ± 24.0 | 0.253 |
HRSQoL-24 Clinical | 56.6 ± 25.8 | 65.8 ± 25.1 | 0.002 |
Domain, Mean ± SD (Points) | Alone, n = 59 | With Family, n = 189 | With Partner, n = 94 | p(ANOVA) |
---|---|---|---|---|
HRSQoL-24 Global | 48.9 ± 22.3 | 62.1 ± 19.7 | 56.6 ± 20.91 | <0.001 |
HRSQoL-24 Psychosocial | 49.6 ± 21.9 | 63.0 ± 20.0 | 56.3 ± 22.6 | <0.001 |
HRSQoL-24 Economic | 42.8 ± 37.7 | 57.8 ± 33.9 | 41.7 ± 36.9 | <0.001 |
HRSQoL-24 Occupational | 48.1 ± 31.7 | 66.9 ± 29.9 | 64.5 ± 31.3 | <0.001 |
HRSQoL-24 Relationships | 58.8 ± 38.7 | 69.0 ± 24.4 | 64.4 ± 25.3 | 0.04 |
HRSQoL-24 Personal | 30.4 ± 23.7 | 39.9 ± 25.1 | 36.7 ± 25.3 | 0.039 |
HRSQoL-24 Clinical | 52.5 ± 28.4 | 65.2 ± 23.7 | 64.8 ± 26.2 | 0.003 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Krajewski, P.K.; Marrón, S.E.; Gomez-Barrera, M.; Tomas-Aragones, L.; Gilaberte-Calzada, Y.; Szepietowski, J.C. The Use of HSQoL-24 in an Assessment of Quality-of-Life Impairment among Hidradenitis Suppurativa Patients: First Look at Real-Life Data. J. Clin. Med. 2021, 10, 5446. https://doi.org/10.3390/jcm10225446
Krajewski PK, Marrón SE, Gomez-Barrera M, Tomas-Aragones L, Gilaberte-Calzada Y, Szepietowski JC. The Use of HSQoL-24 in an Assessment of Quality-of-Life Impairment among Hidradenitis Suppurativa Patients: First Look at Real-Life Data. Journal of Clinical Medicine. 2021; 10(22):5446. https://doi.org/10.3390/jcm10225446
Chicago/Turabian StyleKrajewski, Piotr K., Servando E. Marrón, Manuel Gomez-Barrera, Lucía Tomas-Aragones, Yolanda Gilaberte-Calzada, and Jacek C. Szepietowski. 2021. "The Use of HSQoL-24 in an Assessment of Quality-of-Life Impairment among Hidradenitis Suppurativa Patients: First Look at Real-Life Data" Journal of Clinical Medicine 10, no. 22: 5446. https://doi.org/10.3390/jcm10225446
APA StyleKrajewski, P. K., Marrón, S. E., Gomez-Barrera, M., Tomas-Aragones, L., Gilaberte-Calzada, Y., & Szepietowski, J. C. (2021). The Use of HSQoL-24 in an Assessment of Quality-of-Life Impairment among Hidradenitis Suppurativa Patients: First Look at Real-Life Data. Journal of Clinical Medicine, 10(22), 5446. https://doi.org/10.3390/jcm10225446